Organisations involved in ATMP development

  • Regulatory Science Network Netherlands (RSNN) is an independent broker within the regulatory field. The RSNN Special Interest Group Advanced Therapies aims to identify knowledge gaps and actions to address challenges perceived by stakeholders in ATMP development and assessment. In addition to identification, actions are drafted to address important questions related to current and future ATMP development in a bottom-up fashion, thereby bringing together public and private parties.
  • T2Evolve: to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR).
  • The EBMT is a non-profit medical and scientific organisation that hosts a unique patient registry to advance cellular and stem cell-based therapies to improve lives of patients with blood-related disorders.
  • GoCART is a multi-stakeholder community collaborating to maximise the potential of cellular therapies manufactured from cells and tissues of hematopoietic origin.
  • Cell and Gene Therapy Catapult: CGT Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies, with a vision for a thriving industry delivering life-changing advanced therapies to the world.

Platforms for innovative therapies

  • FAST: the Centre for Future Affordable Sustainable Therapy development (FAST) focuses on keeping the right balance between innovative entrepreneurship and accessible, affordable innovations in therapy development
  • Oncode Accelerator: the preclinical Accelerator for cancer treatment has the ambition to develop new effective cancer drugs faster and more cost-effectively.
  • REGMED XB: Regenerative Medicine Crossing Borders (RegMed XB) is a public-private partnership dedicated to bringing regenerative medicine solutions to patients and creating a new industrial sector in the participating regions.
    • ICAT: the Innovation Center of Advanced Therapies (ICAT) aims to improve and accelerate the translation of research into healthcare solutions by bringing together all relevant expertise and infrastructure for the development of regenerative treatments, Advanced Therapy Medicinal Products (ATMPs) including cell therapy, and disease models.
    • NECSTGEN: the Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) comprises a state-of-the-art facility for development and GMP manufacturing. NecstGen additionally offers cleanroom rental to allow organisations to maintain control of production while de-risking the capital investment required to do so.
  • NXTGEN HIGHTECH: making the world better for our future generation with a new generation of high-tech equipment
  • EATRIS: the European Advanced Translational Research Infrastructure in Medicine, bringing together resources and services for research communities to translate scientific discoveries into benefits for patients.
  • HollandBIO: represents and connects life science companies in the Netherlands with the aim to make biotech innovations quickly and widely available.

Data sharing

  • Health-RI: better health for citizens and patients by reusing health data with an integrated health data infrastructure for research and innovation.